Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 1;2024(67):410-416.
doi: 10.1093/jncimonographs/lgae026.

Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy

Anne E Schuind  1 , Kanduri Ananth Balaji  2 , Anna Du  3 , Yuan Yuan  4 , Peter Dull  5
Affiliations
Review

Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy

Anne E Schuind et al. J Natl Cancer Inst Monogr. .

Abstract

Human papillomavirus (HPV) prophylactic vaccines were first licensed in 2006 with the primary goal of preventing HPV-related cancers, with cervical cancer accounting for the highest morbidity and mortality globally. Six HPV vaccines have been licensed; 4 of these have been prequalified by the World Health Organization, and additional products are in the pipeline. This article provides an overview of HPV vaccine coverage and current and anticipated vaccine supply vs expected demand. Given that the 2022 World Health Organization position paper on HPV vaccines includes a 1-dose regimen as an alternate schedule, we will discuss the evidence for using licensed vaccines in single-dose regimens and the approach to generating similar supportive data for other current and future vaccines. The broad adoption of a single-dose HPV vaccine regimen would expand access to vaccines by improving the supply-demand balance, increasing affordability, and simplifying logistics, which will ultimately impact HPV-related morbidity and mortality.

PubMed Disclaimer

Conflict of interest statement

AD serves as vice chair of the Council for the Promotion of International Vaccine Cooperation under the China Association for Vaccines, is a member of the steering committee for the Chinese vaccinology course, and serves on the scientific advisory board of the fifth vaccine innovation forum China. PD serves on the Coalition for Epidemic Preparedness Innovations scientific advisory committee and is a member of Inventprise scientific advisory board. YY serves as secretary general for the Council for the Promotion of International Vaccine Cooperation under the China Association for Vaccines. AES and KAB have no conflicting interests to report.

Figures

Figure 1.
Figure 1.
Countries having adopted a single-dose human papillomavirus vaccine schedule as of April 23, 2024.
See this image and copyright information in PMC

References

    1. de Martel C, Plummer M, Vignat J, Franceschi S.. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-670. - PMC - PubMed
    1. Bray F, Laversanne M, Sung H, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229-263. doi:10.3322/caac.21834 - DOI - PubMed
    1. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV.. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-265. - PMC - PubMed
    1. World Health Organization (WHO) Immunization, Vaccines and Biologicals. Human Papillomavirus Vaccines: WHO Position Paper. Geneva: WHO; 2022.
    1. UNICEF Supply Division. Closing the Gap: UNICEF Bolsters Country Efforts to Increase HPV Vaccination. April 28, 2023. https://www.unicef.org/supply/stories/closing-gap-unicef-bolsters-countr.... Accessed February 26, 2024.

MeSH terms

Substances